APRIL 16-18, 2019


The 6th Annual Translational Microbiome Conference is Coming Back to Boston in April 2020. 

Please check back in the coming weeks for additional details.

Thought Leader in Microbiome Research Jack Gilbert to Present at Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference

2 December 2016 – Minneapolis, MN – Jack Gilbert, the faculty director of The Microbiome Center and professor at the University of Chicago, has just been announced as the keynote speaker at Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference. This conference will once again unite top companies in the microbiome space working to successfully commercialize microbiome-based diagnostics and therapeutics. This conference will be taking place April 11-13, 2017 in Boston, MA. For more information on the conference, visit: http://www.microbiomeconference.com.

As the human microbiome is quickly demonstrating huge roles in the human ecosystem, scientists are discovering that changes in the microbiome have a huge impact on a variety of conditions and diseases. Dr. Gilbert will discuss the latest evidence of these mechanisms of interaction, and how we have started to disturb the delicate balance of immune-microbe equilibrium, thus impacting the development and function of our immune systems. By applying new strategies to identify how the microbial ecosystem correlates with diseases and treatment efficacy through Microbiome-Wide Association Studies (MWAS), microbiome studies are providing a new framework for facilitating patient care.

With an increasing awareness that many of our modern diseases are “lifestyle” related and more than 50% of current medications are ineffective for the people taking them, research in the microbiome presents a potential opportunity to provide more effective treatments, cures, therapies and supplements. Reflective of this trend is the fact that investment opportunities are growing in this area and many companies are rapidly moving towards potential translational work. 

Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference will continue to focus and build on the challenges and hurdles that companies working in the microbiome space will have to recognize and navigate in order to successfully commercialize their products. With a broad focus spanning multiple disease states (oncology, dermatology, inflammatory disorders, among others), attendees will have the opportunity to hear the leading companies discuss integral components of successful businesses. For more information, visit: http://www.microbiomeconference.com/brochure.

For more information, please contact:

John Waslif: Managing Director

Arrowhead Publishers

866-945-0263 ext 700

This email address is being protected from spambots. You need JavaScript enabled to view it.

Rachel Donlon: Marketing Associate

Arrowhead Publishers

866-945-0263 ext 701

This email address is being protected from spambots. You need JavaScript enabled to view it.


The Microbiome-Vaccine Summit: Microbiome-Mediated Immunity and the Future of Vaccines

Dates and Location: September 2019 | London, United Kingdom

Microbes in the gut have been found to exert profound control over the immune system. The role of the microbiome in modulating the immune response has already been substantially researched with numerous correlations between the microbiome’s immune effects and disease hypothesized and being explored. One exciting area of inquiry is the potential for the microbiome to play a substantial role in vaccine response. This area of exploration includes:

♦ Its potential to change how patients respond to checkpoint inhibition therapy for metastatic melanoma
♦ Correlations between the efficacy of the rotavirus and geographic differences in the gut biome
♦ How the antibiotic-mediated dysbiotic gut microbiome may actually mount a strong immune response to the seasonal flu vaccine
♦ And the gut-lung axis, or the role of the microbiome in the meteoric rise of asthma
♦ And even the possibility of explaining why some children experience adverse reactions to vaccinations, and why our current vaccine protocol starting within 12 hours of birth does not properly factor gut microbiota as crucial to immune response.

An extension of the highly successful Arrowhead Translational Microbiome Conference held every April in Boston, join us for this first event in our Translational Microbiome Spotlight series, where we bring together industry and academic experts considering the interface between the microbiome and vaccines in a one day, highly interactive roundtable forum.

CLICK HERE to request more information. If you are interested in speaking or sponsorship opportunities, please email This email address is being protected from spambots. You need JavaScript enabled to view it..